The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Open accessAbstract
BACKGROUND: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS: We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-to-target, event-driven cardiovascular outcomes trial. The primary composite outcome in the time-to-event analysis was the first occurrence of an adjudicated major cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) with a prespecified noninferiority margin of 1.3. Adjudicated severe hypoglycemia, as defined by the American Diabetes Association, was the prespecified, multiplicity-adjusted secondary outcome. RESULTS: Of the patients who underwent randomization, 6509 (85.2%) had established cardiovascular disease, chronic kidney disease, or both. At baseline, the mean age was 65.0 years, the mean duration of diabetes was 16.4 years, and the mean (±SD) glycated hemoglobin level was 8.4±1.7%; 83.9% of the patients were receiving insulin. The primary outcome occurred in 325 patients (8.5%) in the degludec group and in 356 (9.3%) in the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P<0.001 for noninferiority). At 24 months, the mean glycated hemoglobin level was 7.5±1.2% in each group, whereas the mean fasting plasma glucose level was significantly lower in the degludec group than in the glargine group (128±56 vs. 136±57 mg per deciliter, P<0.001). Prespecified adjudicated severe hypoglycemia occurred in 187 patients (4.9%) in the degludec group and in 252 (6.6%) in the glargine group, for an absolute difference of 1.7 percentage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for superiority). Rates of adverse events did not differ between the two groups. CONCLUSIONS: Among patients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of major cardiovascular events. (Funded by Novo Nordisk and others; DEVOTE ClinicalTrials.gov number, NCT01959529 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Both insulin glargine U100 and insulin degludec have demonstrated cardiovascular safety in dedicated CVOTs (207,208).”
In the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [22]
In the citing paper
“A significantly lower frequency of hypoglycaemia was observed in the degludec arm compared with the glargine arm.181”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [181]
In the citing paper
“The DEVOTE (A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events) trial, a randomized, double-blind comparison of the ultra-long-acting, o.d.insulin degludec vs. insulin glargine U100, enrolled 7637 patients with T2DM with ASCVD or at high CV risk.181 Over a median follow-up of 1.8 years, there”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [181]
In the citing paper
“For example, insulin degludec compared with glargine in the DEVOTE trial reduced the risk of hypoglycaemia, yet this did not translate into any difference in CV risk.181”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Flagged first, then by citations
Research works printed but not linked: 2
- 2001, J Postgrad Med, 47, 199
- Wysham C, 2016, Diabetologia, 59, S43. abstract
Cited by
Sorted by citations
Items 501–572 of 572
Pharmacodynamic Evaluation: Diabetic Methodologies
SANDOW, J. (2019) · Springer eBooks · doi:10.1007/978-3-319-56637-5_33-1
Morales-Villegas, E. C. (2020) · Journal of Heart Health · doi:10.16966/2379-769x.154
New Era of Insulin Preparation for Once Weekly Administration
Bando, H. (2020) · Institutional Repositories DataBase (IRDB)
Maurantonio, M., Gabrielli, F., Castellano, C., Andrea, C., Andreoné, P., & Roncucci, L. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00035
Series: Cardiovascular outcome trials for diabetes drugs Degludec and DEVOTE
Fisher, M. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.302
Piťhová, P. (2021) · Medicína pro praxi · doi:10.36290/med.2021.017
Praktische Umsetzung einer Insulintherapie bei Typ-2-Diabetes
Liebl, A. (2021) · Diabetes aktuell · doi:10.1055/a-1576-9316
Bose, D., & Konwar, M. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210914114511
Carrasco-Sánchez, F. J., Fern�ndez-Rodr�guez, J. M., Escribano, P. P. C., Miramontes-Gonz�lez, J. P., G�mez-Huelgas, R., Garc�a-de-Lucas, M. D., Ena, J., & Carretero-G�mez, J. (2021) · Spanish Journal of Medicine · doi:10.24875/sjmed.21000010
Antidiabéticos en Insuficiencia Cardíaca
Rojas, Z. A. G., Sierra, D. M. C., Papadópulos, A. V. P., & Ormaechea, G. (2021) · Revista Uruguaya de Medicina Interna · doi:10.26445/06.03.1
Which antidiabetic drug indications are recommended for geriatric DM patients?
Mannucci, E. (2021) · Journal of Gerontology and Geriatrics · doi:10.36150/2499-6564-n458
Baran, O., Dersch‐Mills, D., Bakal, J. A., Huyghebaert, T., Hnatiuk, M., & Roedler, R. L. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.12.002
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00765-5
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Tschiedel, B., & Puñales, M. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_32
red (2018) · Info Diabetologie · doi:10.1007/s15034-018-1427-9
Kurian, M. J., Rentzepis, P. J., Carracher, A. M., & Close, K. L. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12920
Maurantonio, M., Gabrielli, F., Castellano, C., Andrea, C., Andreoné, P., & Roncucci, L. (2021) · Exploration of Medicine · doi:10.37349/emed.2020.00035
Monnier, L., & Halimi, S. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00029-4
Omeara, M., Acuña, J. C. M., & Uribe, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1688540/v1
Müller‐Wieland, D., & Marx, N. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_12-1
Omeara, M., Acuña, J. C. M., & Uribe, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1688540/v2
Morales-Villegas, E. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3207
Control of Blood Glucose and Cardiovascular Risk Profile
Ciardullo, S., & Perseghin, G. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_28
Transplantationsmöglichkeiten für Patienten mit Diabetes und fortgeschrittener Niereninsuffizienz
Chatzikyrkou, C. (2023) · Die Diabetologie · doi:10.1007/s11428-022-00995-1
Galstyan, G. R. (2023) · Diabetes Mellitus · doi:10.14341/dm12976
Nedogoda, S. V., Barykina, I. N., Salasyuk, A. S., Lutova, V. O., & Popova, E. A. (2022) · Diabetes Mellitus · doi:10.14341/dm12774
Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?)
Katerenchuk, V. I. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.1.2023.1244
Injektionstherapie (GLP1-Rezeptor Agonisten und Insulin) bei Typ 2 Diabetes mellitus (Update 2023)
Lechleitner, M., Roden, M., Weitgasser, R., Ludvik, B. H., Fasching, P., Hoppichler, F., Kautzky‐Willer, A., Schernthaner, G., Prager, R., Kaser, S., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02171-x
Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual
Peter, P. R., & Inzucchi, S. E. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_37
Heart Failure and Cardiac Dysfunction in Diabetes
Afari, M. E., & Givertz, M. M. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_27
Second Generation Basal Insulin, Degludec, in the Management of Diabetes; Consensus Report
Alsifri, S. N., Alshahrani, A., Aldawish, M., Alyahia, K., Alharbi, B., Moloy, H., Alrumiah, A., Evans, M., Bokhari, S., & Issak, E. R. (2023) · Clinical Reviews & Cases · doi:10.33425/2689-1069.1049
Mannucci, E., & Scoccimarro, D. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_23
Minimizing Hypoglycemia with Insulin Therapy
Priya, G., & Grewal, E. (2022) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_9_22
Murata, T., Husemoen, L. L. N., Nemoto, S., & Matsuhisa, M. (2023) · Diabetology International · doi:10.1007/s13340-023-00657-7
Müller‐Wieland, D., & Marx, N. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_12
How to Use Type 2 Diabetes Treatments in Clinical Practice
Karagiannis, T., Liakos, A., & Τσάπας, Α. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch37
Pandey, A., Patel, K. V., & Verma, S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch50
Sawamura, T., Karashima, S., Ohbatake, A., Higashitani, T., Ohmori, A., Sawada, K., Yamamoto, R., Kometani, M., Katsuda, Y., & Yoneda, T. (2024) · Medicina · doi:10.3390/medicina60030450
Traiter les hypoglycémies iatrogènes à l’ère des nouvelles technologies
Monnier, L., & Colette, C. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.02.002
An update of contemporary insulin therapy
Tsai, Y., Gu, Y., & Jiang, Y. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14212 · Cited by 1
Kiran, G., Sastry, N. G., Kumar, G., Dilipkumar, S., Kalva, L. T., & Sireesha, G. (2024) · International Journal of Medical Arts · doi:10.21608/ijma.2024.271812.1938
Colosimo, S., Ruan, Y., Lumb, A. N., Rea, R. D., McDonald, P., Bain, S. C., Abraham, R. R., GALLEN, I. W., & Ryder, R. E. J. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.448
Kelley, D., Addison, J. D., Janzen, K. M., & Wulfe, S. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1997
Herzinsuffizienz bei Patienten mit Diabetes mellitus
Schütt, K. S., & Polzin, A. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2318-3573
Management of Older Adults with Diabetes According to the 2023 Guidelinesfor Elderly Diabetes
Watanabe, K. (2024) · Journal of Nihon University Medical Association · doi:10.4264/numa.83.2_51
Wang, W., Reynier, P., Webster‐Clark, M., Yu, O. H., Brunetti, V. C., & Filion, K. B. (2024) · medRxiv · doi:10.1101/2024.11.28.24317254
Type 2 Diabetes Mellitus in Youth
Srinivasan, S., & Levitsky, L. L. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_31
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Würfel, M., & Ebert, T. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01331-z
Pawar, A. D., Rohile, S. B., & D., P. S. S. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29628
Müller‐Wieland, D., & Marx, N. (2024) · Springer eBooks · doi:10.1007/978-3-662-69938-6_12
McGuire, D. K., D’Alessio, D., Nicholls, S. J., Nissen, S. E., Riesmeyer, J. S., Pavo, I., Sethuraman, S., Heilmann, C. R., Kaiser, J. J., & Weerakkody, G. J. (2022) · Figshare · doi:10.6084/m9.figshare.20625103
Self-citationLongato, E., Di Camillo, B., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2021) · Figshare · doi:10.6084/m9.figshare.17007077
Wang, W., Reynier, P., Webster‐Clark, M., Yu, O. H. Y., Brunetti, V. C., & Filion, K. B. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70313
Gupta, V., & Khurana, G. (2026) · Cureus · doi:10.7759/cureus.102882
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., Schmitz, S. H., & Subramanian, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00020-3
Prevention of Heart Failure in People With Diabetes
Pandey, A., & Hernandez, A. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00015-x
Antihyperglycemic Medications With Proven Cardiovascular Safety
Green, J. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00014-8
Serial femtosecond crystallography reveals the pH-driven allosteric mechanism of hexamer glarginePreprint
Ayan, E. B., Shankar, M. K., Telek, E., Kang, J., Fintor, K., Yabuuchi, T., Yabashi, M., & Tosha, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.07.716775
Saab, C., Mansour, A. A., Rahmah, A. M., Al-Attar, D. M. R. A., Alrubaye, H. F., Alidrisi, H. A., Nwayyir, H. A., Khudhair, M. S., Ahmed, M. J., AL-Ibrahimi, S. M., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01861-9
Bolli, G. B., Home, P., Lepore, M., Riddle, M. C., Porcellati, F., Fanelli, C. G., Lucidi, P., Yki‐Järvinen, H., Becker, R. H. A., & Owens, D. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70751
Stratégies thérapeutiques dans le traitement du diabète de type 2
Bordier, L., & Bauduceau, B. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(25)49531-6
Les traitements du diabète de type 2 : les preuves
Bordier, L., & Bauduceau, B. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100822
Malkin, S. J. P., Kandalam, S., Guareschi, G., D’Angiolella, L. S., & Hunt, B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71144
Kong, A. P. S., Chun Kwan, O., Lai, S., Wang, C.-Y., & Chan, J. C.-N. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.08.005
Considerations for the Integration of Clinical Trials and Real‐World Data
Qiu, S., Barr, C. E., Dang, L., Han, L., Kvist, K., Lee, H., Mertens, A., Nance, N., Nie, L., Rudolph, K. E., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70513
Self-citation(2026) · ADA Clinical Compendia · doi:10.2337/db20261-33
Nyström, T., Michelsen, J., Imberg, H., Hallström, S., Tasselius, V., Norhammar, A., Petzold, M., Mader, J. K., Choudhary, P., Elzalabany, M. K., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71429
A study of the patient weighted while alive estimand for recurrent events with competing risks
Perme, M. P., Ravn, H., & Andersen, P. K. (2026) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2026.2747969
Metadata
- Authors
- Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., Moses, A., Skibsted, S., Kvist, K., & Buse, J. B.
- Affiliations
- Mount Sinai Hospital (CA)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-24
- Volume
- 377
- Issue
- 8
- Pages
- 723-732
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5731244
- OpenAlex
- W2625031949
- Cited by
- 574
- References
- 27
- Citations by year
- 2026: 20 · 2025: 16 · 2024: 41 · 2023: 43 · 2022: 56 · 2021: 61 · 2020: 81 · 2019: 104 · 2018: 100 · 2017: 50
- FWCI
- 72.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Acibadem University Open Access Repository (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
- Versus Arthritis (20639, 18475)
- National Institutes of Health (UL1TR001111, UL1TR002489)
- National Institute of Diabetes and Digestive and Kidney Diseases (T35DK060444, P30DK020541)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, insulin glargine, type 2 diabetes, basal insulin, cardiovascular safety, major adverse cardiovascular events, severe hypoglycemia, HbA1c, fasting blood glucose, non-inferiority, cardiovascular disease, chronic kidney disease, glycemic variability, insulin duration of action
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Incidence, Insulin, Long-Acting, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
